Filtered By:
Cancer: Acute Leukemia
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 260 results found since Jan 2013.
MEK inhibitor CI-1040 induces apoptosis in acute myeloid leukemia cells in vitro.
CONCLUSIONS: These results demonstrate that CI-1040 induce apoptosis of U-937 cells and might be a new therapeutic option for the treatment of AML.
PMID: 27249593 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - June 3, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells
Publication date: 1 May 2016 Source:Life Sciences, Volume 152 Author(s): Saeed Mohammadi, Seyed H. Ghaffari, Mojgan Shaiegan, Mahin Nikougoftar Zarif, Mohsen Nikbakht, Shiva Akbari Birgani, Kamran Alimoghadam, Ardeshir Ghavamzadeh Aims Acute myeloid leukemia (AML) initiation and progression have been attributed to subpopulations of self-renewing leukemia stem cells (LSCs), which contribute to progression, recurrence and therapeutic resistance in leukemia. Osteopontin (OPN) plays an important role in promoting survival and drug resistance in LSCs. The aim of this study was to explore OPN roles in modulating curcum...
Source: Life Sciences - May 2, 2016 Category: Biology Source Type: research
Silencing of myeloid cell leukemia-1 by small interfering RNA improves chemosensitivity to etoposide in u-937 leukemic cells.
Authors: Jafarlou M, Baradaran B, Shanehbandi D, Saedi TA, Jafarlou V, Karimi P, Othman F
Abstract
A key issue in the treatment of acute myeloid leukemia (AML) is the development of drug resistance to chemotherapeutic agents. Overexpression of myeloid cell leukemia-1 (Mcl-1), an anti-apoptotic protein, is associated with tumor progression and drug resistance in leukemia and several cancers. The purpose of this study was to investigate the effect of specific Mcl-1 small interference RNA (siRNA) on the proliferation and chemosensitivity of U-937 AML cell to etoposide. The siRNA transfection was conducted using Lipofe...
Source: Journal of Biological Regulators and Homeostatic Agents - April 8, 2016 Category: Biomedical Science Tags: J Biol Regul Homeost Agents Source Type: research
Anti‐leukaemic effects induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells
In conclusion, ROS induction is important for antileukaemic activities of APR‐246 and inhibiting the protective response of the Nrf‐2/HMOX1 axis using PI3K inhibitors, enhances the antileukaemic effects.
Source: British Journal of Haematology - March 15, 2016 Category: Hematology Authors: Dina Ali, Dara K. Mohammad, Huthayfa Mujahed, Kerstin Jonson‐Videsäter, Beston Nore, Christer Paul, Sören Lehmann Tags: Research Paper Source Type: research
CD56 and RUNX1 isoforms in AML prognosis and their therapeutic potential
Publication date: Available online 12 December 2015 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Syed Z.A. Zaidi, Ibraheem H. Motabi, Ali Al-Shanqeeti Neural cell adhesion molecule (NCAM/CD56) expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia, multidrug resistance, shorter remission and survival. Recently, Bloomfield et al. published a succinct review of issues surrounding the AML prognostication and current therapeutics. However, we want to reiterate the prognostic value and therapeutic potential of CD56 that is frequently expressed in AML as was also reported ...
Source: Hematology Oncology and Stem Cell Therapy - March 7, 2016 Category: Cancer & Oncology Source Type: research
Effect of silencing HOXA5 gene expression using RNA interference on cell cycle and apoptosis in Jurkat cells.
Abstract
Acute lymphocytic leukemia (ALL) is a common malignant tumor with a high morbidity rate among children, accounting for approximately 80% of leukemia cases. Although there have been improvements in the treatment of patients frequent relapse lead to a poor prognosis. The aim of the present study was to determine whether HOXA5 may be used as a target for gene therapy in leukemia in order to provide a new treatment. Mononuclear cells were extracted from the bone marrow according to the clinical research aims. After testing for ALL in the acute stage, the relative mRNA and protein expression of HOXA5 was detec...
Source: International Journal of Molecular Medicine - February 4, 2016 Category: Molecular Biology Authors: Huang HP, Liu WJ, Guo QL, Bai YQ Tags: Int J Mol Med Source Type: research
ABCC4 Is a Determinant of Cytarabine‐Induced Cytotoxicity and Myelosuppression
Resistance to cytarabine remains a major challenge in the treatment of acute myeloid leukemia (AML). Based on previous studies implicating ABCC4/MRP4 in the transport of nucleosides, we hypothesized that cytarabine is sensitive to ABCC4‐mediated efflux, thereby decreasing its cytotoxic response against AML blasts. The uptake of cytarabine and its monophosphate metabolite was found to be facilitated in ABCC4‐expressing vesicles and intracellular retention was significantly impaired by overexpression of human ABCC4 or mouse Abcc4 (P < 0.05). ABCC4 was expressed highly in AML primary blasts and cell lines, and cytotoxi...
Source: Clinical and Translational Science - February 4, 2016 Category: Biomedical Science Authors: CD Drenberg, S Hu, L Li, DR Buelow, SJ Orwick, AA Gibson, JD Schuetz, A Sparreboom, SD Baker Tags: ARTICLE Source Type: research
Expression and functional roles of the chemokine receptor CXCR7 in acute myeloid leukemia cells.
CONCLUSION: CXCR7 is involved in the regulation of autocrine CXCL12 in AML cells.
PMID: 26770949 [PubMed]
Source: Blood Research - January 18, 2016 Category: Hematology Tags: Blood Res Source Type: research
Ginkgolide B protects human umbilical vein endothelial cells against xenobiotic injuries via PXR activation.
CONCLUSION: Ginkgolide B exerts anti-apoptotic and anti-inflammatory effects on endothelial cells via PXR activation, suggesting that a PXR-mediated endothelial detoxification program may be important for protecting endothelial cells from xeno- and endobiotic-induced injuries.
PMID: 26775663 [PubMed - as supplied by publisher]
Source: Acta Pharmacologica Sinica - January 18, 2016 Category: Drugs & Pharmacology Authors: Zhou T, You WT, Ma ZC, Liang QD, Tan HL, Xiao CR, Tang XL, Zhang BL, Wang YG, Gao Y Tags: Acta Pharmacol Sin Source Type: research
T-cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T cell Exhaustion and Poor Clinical Outcome in AML Patients.
CONCLUSION: TIGIT contributes to functional T cell impairment and associates with poor clinical outcome in AML. Our study suggests that blockade of TIGIT to restore T cell function and antitumor immunity may represent a novel effective leukemia therapeutic.
PMID: 26763253 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 13, 2016 Category: Cancer & Oncology Authors: Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka W, George MR, Zeng H, Zheng H Tags: Clin Cancer Res Source Type: research
Abstract C178: TAS4464, a novel NEDD8 activating enzyme inhibitor, potently induces cell death via both intrinsic and extrinsic apoptotic pathways in acute myeloid leukemia
CONCLUSION: TAS4464 exerts a strong apoptosis-inducing effect in AML cell lines via both intrinsic and extrinsic apoptotic pathway by modulating apoptosis-related proteins. In addition, TAS4464 demonstrates marked antitumor activity in the THP-1 xenograft model. Given its potent preclinical activities, TAS4464 is a promising agent for treating AML.Citation Format: Hiroaki Ochiiwa, Chihoko Yoshimura, Hiromi Muraoka, Keiji Ishida, Tomonori Haruma, Shingo Tsuji, Akihiro Hashimoto, Takashi Mizutani, Shuichi Ohkubo, Kenichi Matsuo, Teruhiro Utsugi, Yoshikazu Iwasawa. TAS4464, a novel NEDD8 activating enzyme inhibitor, potently ...
Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Ochiiwa, H., Yoshimura, C., Muraoka, H., Ishida, K., Haruma, T., Tsuji, S., Hashimoto, A., Mizutani, T., Ohkubo, S., Matsuo, K., Utsugi, T., Iwasawa, Y. Tags: Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts Source Type: research
Alternative Splicing of CD19 Enables Resistance to CART-19 Research Articles
This article is highlighted in the In This Issue feature, p. 1225
Source: Cancer Discovery - December 3, 2015 Category: Cancer & Oncology Authors: Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., Martinez, N. M., Harrington, C. T., Chung, E. Y., Perazzelli, J., Hofmann, T. J., Maude, S. L., Raman, P., Barrera, A., Gi Tags: Research Articles Source Type: research
MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation
In this study, we explored the effect of MPT0B169 on apoptosis in AML HL60 and NB4 cells and MDR1-mediated taxol-resistant HL60/TaxR cells and the underlying mechanism. MPT0B169 induced concentration- and time-dependent apoptosis in these cancer cells, as observed through annexin V/propidium iodide double staining and flow cytometry. Furthermore, DNA fragmentation analysis confirmed MPT0B169-induced apoptosis. MPT0B169 induced a loss of mitochondrial membrane potential, release of cytochrome c into the cytosol, cleavage and activation of caspase-9 and caspase-3, and consequently cleavage of poly (ADP ribose) polymerase. We...
Source: Tumor Biology - November 25, 2015 Category: Cancer & Oncology Source Type: research
Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts
Conclusion: These data suggest that PML sumoylation is required for ATO-induced collagen synthesis in osteoblasts.Cell Physiol Biochem 2015;37:1581-1591
Source: Cellular Physiology and Biochemistry - October 31, 2015 Category: Cytology Source Type: research
Sorafenib inhibition of Mcl-1 accelerates ATRA induced apoptosis in differentiation responsive AML cells.
CONCLUSIONS: Inhibition of Mcl-1 is required for apoptosis induction in ATRA differentiation responsive AML cells. ATRA and Sorafenib can be developed as a novel drug combination therapy for AML patients because this drug combination augments apoptosis by inhibiting Bcl-2 and Mcl-1.
PMID: 26459180 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 12, 2015 Category: Cancer & Oncology Authors: Wang R, Xia L, Gabrilove JL, Waxman S, Jing Y Tags: Clin Cancer Res Source Type: research
